Evidence-based approach best for cancer management tools

Anaheim, Calif. - Topical imiquimod, systemic retinoids, and sentinellymph node biopsies are dermatologic tools that instigate promise and controversywhen discussing their role in managing basal cell carcinoma, squamous cellcarcinoma, and primary cutaneous melanoma, respectively.

Related Videos
Related Content

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.